Drug Profile
Captisol-enabled paracetamol - Seelos Therapeutics
Alternative Names: Captisol-enabled acetaminophen; CE-acetaminophen; SLS-012Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Class Acetanilides; Aminophenols; Antipyretics; Non-opioid analgesics; Small molecules
- Mechanism of Action Prostaglandin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 10 Oct 2023 Captisol-enabled paracetamol is still in preclinical development for Pain in USA (Seelos Therapeutics pipeline, October 2023)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Pain in USA (IV)
- 17 Dec 2020 Captisol-enabled paracetamol is still in preclinical trials for Pain in USA as of December 2020 (Seelos Therapeutics pipeline)